| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The primary target of Cimiracemoside C is AMPK (AMP-activated protein kinase). It acts as an AMPK agonist/activator. By activating AMPK, it influences cellular energy homeostasis and may exert anti-diabetic effects.
|
|---|---|
| ln Vitro |
In cell-free systems, Cimiracemoside C's activity is assessed by its ability to directly activate AMPK. This is typically measured using an in vitro kinase assay where the compound's effect on AMPK phosphorylation and activity is determined. It activates AMPK. Cellular assays are performed to evaluate Cimiracemoside C's effect on AMPK activation and downstream signaling. Cells are treated with the compound, and the phosphorylation of AMPK and its downstream targets (e.g., ACC) is measured by Western blot. Its effects on glucose uptake and lipid metabolism are also assessed.
|
| ln Vivo |
Cimiracemoside C has been shown to reduce body weight in studies with Cimicifuga racemosa extract Ze 450, which contains this compound. This suggests potential in vivo activity related to metabolic regulation, consistent with its AMPK-activating properties.
|
| Enzyme Assay |
In vitro AMPK activation assays use purified AMPK enzyme. The compound is incubated with AMPK and its substrate (e.g., SAMS peptide) in the presence of ATP. The incorporation of phosphate into the substrate is measured using radioactive or fluorescence-based methods to determine the compound's EC50.
|
| Cell Assay |
Cell-based assays are conducted in hepatocytes or muscle cells. Cells are treated with Cimiracemoside C, and AMPK phosphorylation (p-AMPK) is measured by Western blot. The expression of genes involved in glucose and lipid metabolism is analyzed by qPCR to confirm AMPK pathway activation.
|
| Animal Protocol |
In vivo studies have been performed using Cimicifuga racemosa extracts containing Cimiracemoside C. These studies have shown significant reduction in body weight in animal models. However, the specific contribution of Cimiracemoside C to these effects needs further validation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Cimiracemoside C is not well-characterized. As a glycoside, its oral bioavailability may be limited due to poor absorption and potential metabolism by gut microbiota. Its physicochemical properties (LogP 5.82) suggest high lipophilicity.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Cimiracemoside C is not fully established. It is generally considered safe for research purposes. As a component of black cohosh, it may share some of the herb's safety concerns, though isolated compounds are typically used at lower concentrations.
|
| References | |
| Additional Infomation |
Cimiracemoside C has been reported in white cohosh (Actaea dahurica), high cohosh (Actaea elata), and other organisms with relevant data. See also: black cohosh (partial).
Cimiracemoside C is a research compound with potential anti-diabetic activity. It is a valuable tool for studying the AMPK signaling pathway and its role in metabolic diseases. It is not an approved drug and is for research use only. |
| Molecular Formula |
C35H56O9
|
|---|---|
| Molecular Weight |
620.8138
|
| Exact Mass |
620.392
|
| CAS # |
256925-92-5
|
| PubChem CID |
15541911
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
740.3±60.0 °C at 760 mmHg
|
| Melting Point |
258-260℃
|
| Flash Point |
401.5±32.9 °C
|
| Vapour Pressure |
0.0±5.5 mmHg at 25°C
|
| Index of Refraction |
1.607
|
| LogP |
5.82
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
44
|
| Complexity |
1210
|
| Defined Atom Stereocenter Count |
17
|
| SMILES |
C[C@@H]1C[C@@H]2[C@H](O[C@]3([C@H]1[C@]4(CC[C@@]56C[C@@]57CC[C@@H](C([C@@H]7CC[C@H]6[C@@]4([C@H]3O)C)(C)C)O[C@H]8[C@@H]([C@H]([C@H](CO8)O)O)O)C)O2)C(C)(C)O
|
| InChi Key |
BTPYUWOBZFGKAI-BKJHYQRZSA-N
|
| InChi Code |
InChI=1S/C35H56O9/c1-17-14-19-26(30(4,5)40)44-35(43-19)25(17)31(6)12-13-34-16-33(34)11-10-22(42-27-24(38)23(37)18(36)15-41-27)29(2,3)20(33)8-9-21(34)32(31,7)28(35)39/h17-28,36-40H,8-16H2,1-7H3/t17-,18+,19-,20+,21+,22+,23+,24-,25-,26+,27+,28-,31-,32-,33-,34+,35+/m1/s1
|
| Chemical Name |
(2S,3R,4S,5S)-2-[[(1S,2R,3S,4R,7R,9S,12R,14S,17R,18R,19R,21R,22S)-2-hydroxy-22-(2-hydroxypropan-2-yl)-3,8,8,17,19-pentamethyl-23,24-dioxaheptacyclo[19.2.1.01,18.03,17.04,14.07,12.012,14]tetracosan-9-yl]oxy]oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5 mg/mL (~8.05 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.5 mg/mL (0.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 0.5 mg/mL (0.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6108 mL | 8.0540 mL | 16.1080 mL | |
| 5 mM | 0.3222 mL | 1.6108 mL | 3.2216 mL | |
| 10 mM | 0.1611 mL | 0.8054 mL | 1.6108 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
